Target intelligence / Profile preview

Melanoregulin (MREG)

Target
MREG
Molecular classification
Other (cargo-recognition protein, non-enzymatic, non-receptor), Lysosome- and melanosome-associated membrane protein
01

Overview

Melanoregulin (MREG) is a small, highly charged, multiply-palmitoylated membrane-associated protein involved in the regulation of vesicular transport, especially within melanosomes and lysosome-related organelles. It couples cytoplasmic vesicles to the transport machinery and plays a role in pigmentation by facilitating melanosome transfer from melanocytes to keratinocytes. MREG is critical for lysosomal and phagosome maturation in retinal pigment epithelial cells, where its loss leads to accumulation of undigested material and lipofuscin. It is not homologous to canonical motor or transport proteins but affects organelle motility in a myosin-independent manner. MREG may act as a tumor suppressor in thyroid cancer, with its downregulation associated with increased cell invasion and proliferation. Its structure is characterized by six α-helices and a cholesterol recognition sequence, and its localization and function are dependent on post-translational lipidation and membrane cholesterol content. There is no evidence for MREG being a therapeutic target in conventional pharmacology (such as a receptor, enzyme, or transporter).

Other names
MREGDSUWDT2Dilute suppressor protein homologWhn-dependent transcript 2FLJ10116HDCGA21P
02

Mechanism of action

Not applicable (not a known direct drug target)

03

Biological functions

Melanosome transportCargo sortingPhagosome and lysosome biogenesis/maturationPigmentation regulationLC3-associated phagocytosis in retinal pigment epithelial cellsOrganelle motility (microtubule minus end-directed transport)
04

Disease associations

Pigmentation disorders (murine coat color mutants)Griscelli syndrome (animal models)Retinal degenerative diseases (lipofuscin accumulation due to defective phagosome digestion)Cancer: tumor suppressor role in thyroid cancer (suppresses cell invasion and proliferation via Akt-mTOR)(Putative) airflow/pulmonary function association, by genetic linkage in chromosome 2q
05

Safety considerations

None directly reported as therapeutic challenges, since it is not a drug targetKnockdown or genetic loss may cause defective lysosomal digestion and retinal pigment epithelial dysfunction, and pigment disorders
06

Interacting drugs

None reported in current literature or databases
07

Biomarkers

Loss or downregulation of MREG expression may be a negative prognostic biomarker in thyroid cancerMREG expression could, in theory, be monitored as a biomarker for lysosomal dysfunction in retinal disease models

Beyond the preview

Go deeper on Melanoregulin (MREG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melanoregulin (MREG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call